CM
RXRX icon

Cercano Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Cercano Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-685,018
Closed -$4.51M – 196
2024
Q3 		$4.51M Hold
685,018
– – 0.11% 77
2024
Q2 		$5.14M Hold
685,018
– – 0.14% 76
2024
Q1 		$6.83M Hold
685,018
– – 0.19% 73
2023
Q4 		$6.75M Hold
685,018
– – 0.22% 65
2023
Q3 		$5.24M Sell
685,018
-293,033
-30% -$2.92M 0.19% 70
2023
Q2 		$7.31M Hold
978,051
– – 0.25% 70
2023
Q1 		$6.52M Hold
978,051
– – 0.26% 68
2022
Q4 		$7.54M Buy
+978,051
New +$9.59M 0.31% 63

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Cercano Management's RXRX Position: Q4 2024 in Review

Cercano Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2024, closing a stake of 685,018 shares — an estimated $4.51M sold.

Cercano Management first reported a position in RXRX in Q4 2022 and held it in 8 quarters. The position peaked at $7.54M in Q4 2022. 316 funds tracked by Wall St. Rank hold RXRX as of Q4 2024.

  • Cercano Management reported no remaining Recursion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cercano Management sold 685,018 Recursion Pharmaceuticals shares in Q4 2024, an estimated $4.51M.
  • Cercano Management first reported a position in Recursion Pharmaceuticals in Q4 2022 and held it in 8 quarters.
  • Cercano Management's Recursion Pharmaceuticals position peaked at $7.54M in Q4 2022.
  • 316 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2024.

Based on Cercano Management's 13F filing for Q4 2024, filed 14 Feb 2025.